Finally, we test our theory experimentally by engineering several of the most common clinically observed mutations to TKI therapy in EGFR-driven NSCLC and compete these mutants against the TKI-sensitive ancestor. This evidence concerns the gene EGFR and non-small cell lung carcinoma.